BIOATLA INC (BCAB) Stock Price, Quote, News and Overview
NASDAQ:BCAB - Nasdaq - US09077B1044 - Common Stock - Currency: USD
BCAB Quote, Performance and Key Statistics
0.558
+0.06 (+12.25%)
The current stock price of BCAB is 0.558 USD. In the past month the price increased by 86.06%. In the past year, price decreased by -82.83%.
BCAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.56B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.18B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About BCAB
Company Profile
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Company Info
BIOATLA INC
11085 Torreyana Road
San Diego CALIFORNIA 92121 US
CEO: Jay M. Short
Employees: 65
Company Website: https://www.bioatla.com/
Investor Relations: https://ir.bioatla.com/
Phone: 18585580708
BIOATLA INC / BCAB FAQ
What is the stock price of BIOATLA INC today?
The current stock price of BCAB is 0.558 USD. The price increased by 12.25% in the last trading session.
What is the ticker symbol for BIOATLA INC stock?
The exchange symbol of BIOATLA INC is BCAB and it is listed on the Nasdaq exchange.
On which exchange is BCAB stock listed?
BCAB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOATLA INC stock?
10 analysts have analysed BCAB and the average price target is 8.5 USD. This implies a price increase of 1423.29% is expected in the next year compared to the current price of 0.558. Check the BIOATLA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOATLA INC worth?
BIOATLA INC (BCAB) has a market capitalization of 32.59M USD. This makes BCAB a Nano Cap stock.
How many employees does BIOATLA INC have?
BIOATLA INC (BCAB) currently has 65 employees.
Is BIOATLA INC (BCAB) expected to grow?
The Revenue of BIOATLA INC (BCAB) is expected to decline by -100% in the next year. Check the estimates tab for more information on the BCAB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOATLA INC (BCAB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BCAB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BCAB, evaluating the profitability, health, valuation and growth aspects
- BIOATLA INC (BCAB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOATLA INC (BCAB) Sales and EPS estimates to see what analysts future expectations are.
- BIOATLA INC (BCAB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOATLA INC (BCAB) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOATLA INC (BCAB) Stock Chart to make your own analysis
- BIOATLA INC (BCAB) Latest news and press-releases to stay up to date.
Does BIOATLA INC (BCAB) stock pay dividends?
BCAB does not pay a dividend.
When does BIOATLA INC (BCAB) report earnings?
BIOATLA INC (BCAB) will report earnings on 2025-05-08.
What is the Price/Earnings (PE) ratio of BIOATLA INC (BCAB)?
BIOATLA INC (BCAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.44).
What is the Short Interest ratio of BIOATLA INC (BCAB) stock?
The outstanding short interest for BIOATLA INC (BCAB) is 7.69% of its float. Check the ownership tab for more information on the BCAB short interest.
BCAB Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BCAB. When comparing the yearly performance of all stocks, BCAB is a bad performer in the overall market: 86.15% of all stocks are doing better.
BCAB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BCAB. While BCAB seems to be doing ok healthwise, there are quite some concerns on its profitability.
BCAB Financial Highlights
Over the last trailing twelve months BCAB reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS increased by 44.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -133.1% | ||
| ROE | -489.14% | ||
| Debt/Equity | 0 |
BCAB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to BCAB. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 11.28% and a revenue growth -100% for BCAB